Final remarks and presentation of awards.
FDA Approves Obecabtagene Autoleucel in B-Cell ALL
Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Uproleselan Combo Does Not Improve EFS Vs Chemo in Newly Diagnosed AML
Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications
The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia
In a multicenter study, researchers have a phase 1, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy, aimed at treating adults with relapsed/refractory AML.